Revision 1

#14613 Store at -20C

MKL2/MRTF-B Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source:	UniProt ID:	Entrez-Gene Id:
WB, IP	H M	Endogenous	145	Rabbit	#Q9ULH7	57496

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

MKL2/MRTF-B Antibody recognizes endogenous levels of total MKL2/MRTF-B protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln1081 of human MKL2/MRTF-B protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The megakaryoblastic leukemia proteins 1 and 2 (MKL1, MKL2) are myocardin-related transcription factors (MRTF-A, MRTF-B) that serve as actin-regulated transcription coactivators for the serum response factor (SRF). Interaction between G-actin and MKL proteins retains the coactivator within the cytoplasm of resting cells. Activated Rho-A promotes F-actin assembly and a reduction of the G-actin pool in serum-stimulated cells. This results in the accumulation of MKL proteins in the nucleus, where the coactivator associates with the SRF to activate target gene transcription and mediate multiple cellular processes (1-4). A number of other signaling pathways, including the TGFβ, BMP, and PDGF pathways, also make use of MKL-mediated activation of target gene transcription (5-9). Chromosomal translocations involving the genes encoding MKL1 and MKL2 have been identified in several cases of acute megakaryoblastic leukemia and chondroid lipoma (10-12).

Background References

1. Olson, E.N. and Nordheim, A. (2010) *Nat Rev Mol Cell Biol* 11, 353-65.
2. Knöll, B. (2010) *Biol Chem* 391, 591-7.
3. Cen, B. et al. (2004) *J Cell Biochem* 93, 74-82.
4. Pipes, G.C. et al. (2006) *Genes Dev* 20, 1545-56.
5. O'Connor, J.W. and Gomez, E.W. (2013) *PLoS One* 8, e83188.
6. Scharenberg, M.A. et al. (2014) *J Cell Sci* 127, 1079-91.
7. Wang, D. et al. (2012) *J Biol Chem* 287, 28067-77.
8. Lundquist, M.R. et al. (2014) *Cell* 156, 563-76.
9. Vasudevan, H.N. and Soriano, P. (2014) *Dev Cell* 31, 332-44.
10. Huang, D. et al. (2010) *Genes Chromosomes Cancer* 49, 810-8.
11. Flucke, U. et al. (2013) *Histopathology* 62, 925-30.
12. Ma, Z. et al. (2001) *Nat Genet* 28, 220-1.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster
X: Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse
GP: Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.